GENENT.053CP2

RECEIVEL

MAR PATENTEL

IN THE UNITED STATES PATENT AND TRADEMARK OF FROM 1600/2900 Group Art Unit: 1647 Carter et al. **Applicant** ර**ා**8/779,457 App. X unuary 7, 1997 Filed WSX RECEPTOR AGONIST For **ANTIBODIES** Examiner G. Draper

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing fifteen (15) references that are also enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c)(2) before the mailing date of a final action and before the mailing date of a Notice of Allowance. This statement is accompanied by the fee set forth in 37 C.F.R. § 1.17(p). A duplicate copy of this Statement is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 12

By:

Ginger R. Dreger

Registration No. 33,055

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(415) 954-4114

W:\DOC\$\ANM\ANM-1420.DOC 031201

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. GENENT,053CP2

APPLICATION NO. 08/779,457

MAR 2 0 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT Matthews

TECH CENTER 1600/2900

(USE SEVERAL SHEETS IN NETES EN

FILING DATE January 7, 1997

GROUP 1647

MAR	1	5	2001	, m	·
				Ĕ	U.S. PATENT DOCUMEN

	, <u> </u>	EN.	, st.			, · · · · · · · · · · · · · · · · · · ·	
EXAMINER INITIAL		DOCUMENT NUMBERADE	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,827,734	10/27/98	Weigle et al.	435	325	10/04/95
	2	5,856,098	01/05/99	Snodgrass et al.	435	. 6	01/18/96
	3	5,858,967	01/12/99	Weigle et al.	514	2	09/19/97
	4	5,882,860	03/16/99	Snodgrass et al.	435	6	01/18/96
· · · ·	5	6,001,968	12/14/99	Friedman et al.	530	350	08/17/94
	6	6,124,439	09/26/00	Friedman et al.	530	388.24	06/07/95

	FOREIGN PATENT DOCUMENTS							
EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL							YES	NO
	7	WO 96/31526	10.10.96	PCT				
•	8	WO 97/12037	03.04.97	PCT				
	9	WO 97/26335	24.07.97	PCT	A61K	48/00		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
		H. Baumann et al., "The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors," Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 8374-8378 (August 1996).				
	11	B. D. Bennett et al., "A role for leptin and its cognate receptor in hematopoiesis," <u>Current Biology</u> , Vol. 6, No. 9, pp. 1170-1180 (1996).				
	12	B. Burguera et al., "The Long Form of the Leptin Receptor (OB-Rb) is Widely Expressed in the Human Brain," Neuroendocrinology, Vol. 61, pp. 187-195 (2000).				
	13	S. C. Chua Jr. et al., "Phenotypes of Mouse diabetes and Rat fatty Due to Mutations in the OB (Leptin) Receptor," Science, Vol. 271, pp. 994-996 (February 16, 1996).				
	14	N. Hoggard et al., "Ontogeny of the expression of leptin and its receptor in the murine fetus and placenta," British Journal of Nutrtion, Vol. 83, pp. 317-326 (2000).				
		S-M Luoh et al., "Cloning and characterization of a human leptin receptor using a biologically ctive leptin immunoadhesin," <u>Journal of Molecular</u> Endocrinology, Vol. 18, pp. 77-85 (1997).				

W:\DOCS\ANM\ANM-1388.DOC 022801

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.





I hereby certify that this correspondence and all

marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner

March 13, 2001

(Date)

for Patents, Washington, D.C. 20231, on

MAR 2 U 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Carter et al.

Appl. No.

08/779,457

Filed

January 7, 1997

For

WSX RECEPTOR AGONIST

ANTIBODIES

Examiner

G. Draper

Group Art Unit:

1647

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) Form PTO-1449 with fifteen (15) references.
- (X) Check in the amount of \$180.00.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410. A duplicate copy of this sheet is enclosed.
- (X) Return prepaid postcard.

Ginger R. Dreger

Registration No. 33,055

Attorney of Record